BioStem Technologies, Inc. - 10-Q Filing

BioStem Technologies reports Q3 2026 results featuring complex capital structure including Series A and B convertible preferred shares and multiple bridge loan notes.

SEC EDGAR ·

Tickers: $BSEM

Read the full article at SEC EDGAR

More Regulatory news